BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Woo HY, Heo J. New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis. Clin Mol Hepatol 2015;21:115-21. [PMID: 26157747 DOI: 10.3350/cmh.2015.21.2.115] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Choi HS, Kang KM, Jeong BK, Jeong H, Lee YH, Ha IB, Song JH. Effectiveness of stereotactic body radiotherapy for portal vein tumor thrombosis in patients with hepatocellular carcinoma and underlying chronic liver disease. Asia Pac J Clin Oncol 2021;17:209-15. [PMID: 32757461 DOI: 10.1111/ajco.13361] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Su F, Chen KH, Liang ZG, Wu CH, Li L, Qu S, Chen L, Zhu XD, Zhong JH, Li LQ, Xiang BD. Comparison of three-dimensional conformal radiotherapy and hepatic resection in hepatocellular carcinoma with portal vein tumor thrombus. Cancer Med 2018;7:4387-95. [PMID: 30062844 DOI: 10.1002/cam4.1708] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
3 Kim MA, Jang H, Choi NR, Nam JY, Lee YB, Cho EJ, Lee JH, Yu SJ, Kim HC, Chung JW, Yoon JH, Kim YJ. Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study. J Hepatocell Carcinoma 2021;8:1565-77. [PMID: 34909425 DOI: 10.2147/JHC.S335879] [Reference Citation Analysis]
4 Yang H, Woo HY, Lee SK, Han JW, Jang B, Nam HC, Lee HL, Lee SW, Song DS, Song MJ, Oh JS, Chun HJ, Jang JW, Lozada A, Bae SH, Choi JY, Yoon SK. A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function. Clin Mol Hepatol. 2017;23:128-137. [PMID: 28494528 DOI: 10.3350/cmh.2016.0071] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
5 Abdelmaksoud AHK, Abdelaziz AO, Nabeel MM, Hamza I, Elbaz TM, Shousha HI, Abdelhady RSM, Lithy R. Hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein thrombosis: a case-control study. Clin Radiol 2021;76:709.e1-6. [PMID: 34116796 DOI: 10.1016/j.crad.2021.03.022] [Reference Citation Analysis]
6 Ye SL, Chen X, Yang J, Bie P, Zhang S, Liu F, Liu L, Zhou J, Dou K, Yip CS, Yang X. Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data. Tumour Biol 2017;39:1010428317695030. [PMID: 28349781 DOI: 10.1177/1010428317695030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
7 Li L, Cheng N, Huang X, Weng X, Jiao Y, Liu J, Guo W. Efficacy and safety of endovascular brachytherapy combined with transarterial chemoembolization for the treatment of hepatocellular carcinoma patients with type III or IV portal vein tumor thrombosis. World J Surg Oncol 2022;20:30. [PMID: 35109883 DOI: 10.1186/s12957-022-02495-4] [Reference Citation Analysis]
8 Zhu J, Yin T, Xu Y, Lu XJ. Therapeutics for advanced hepatocellular carcinoma: Recent advances, current dilemma, and future directions. J Cell Physiol. 2019;234:12122-12132. [PMID: 30644100 DOI: 10.1002/jcp.28048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
9 Kuo F, Cheng T, Cheng Y, Wu C, Wang C. Effectiveness of multimodality treatment for hepatocellular carcinoma patients with portal vein thrombosis: A real world experience. Adv in Digestive Med. [DOI: 10.1002/aid2.13275] [Reference Citation Analysis]
10 Ding SM, Lu AL, Lu JF, Chen XL, Edoo MIA, Zhou L, Xie HY, Zheng SS, Li QY. Macrovascular Endothelial Cells Enhance the Motility of Liver Cancer Cells by Up-regulation of MMP-3, Activation of Integrin/FAK Signaling Pathway and Induction of Non-classical Epithelial-mesenchymal Transition. J Cancer 2020;11:2044-59. [PMID: 32127932 DOI: 10.7150/jca.38209] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Kim SS, Cho HJ, Nam JS, Kim HJ, Kang DR, Won JH, Kim J, Kim JK, Lee JH, Kim BH, Lee MY, Cho SW, Cheong JY. Plasma MicroRNA-21, 26a, and 29a-3p as Predictive Markers for Treatment Response Following Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. J Korean Med Sci 2018;33:e6. [PMID: 29215815 DOI: 10.3346/jkms.2018.33.e6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
12 Meng X, Wang L, Zhu B, Zhang J, Guo S, Li Q, Zhang T, Zheng Z, Wu G, Zhao Y. Integrated Bioinformatics Analysis of the Clinical Value and Biological Function of ATAD2 in Hepatocellular Carcinoma. Biomed Res Int 2020;2020:8657468. [PMID: 32462022 DOI: 10.1155/2020/8657468] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Ahn YE, Suh SJ, Yim HJ, Seo YS, Yoon EL, Kim TH, Lee YS, Yim SY, Kim HR, Kang SH, Jung YK, Kim JH, Yeon JE, Um SH, Byun KS. Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Gut Liver. 2021;15:284-294. [PMID: 32307975 DOI: 10.5009/gnl19367] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
14 Im JH, Yoon SM, Park HC, Kim JH, Yu JI, Kim TH, Kim JW, Nam TK, Kim K, Jang HS, Kim JH, Kim MS, Yoon WS, Jung I, Seong J. Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area. Liver Int. 2017;37:90-100. [PMID: 27317941 DOI: 10.1111/liv.13191] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 5.5] [Reference Citation Analysis]
15 Lee WC, Chou HS, Wu TJ, Lee CF, Hsu PY, Hsu HY, Wu TH, Chan KM. Down-regulation of metabolic proteins in hepatocellular carcinoma with portal vein thrombosis. Clin Proteomics 2017;14:29. [PMID: 28785178 DOI: 10.1186/s12014-017-9164-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
16 Lee HW, Kim HS, Kim SU, Kim DY, Kim BK, Park JY, Ahn SH, Jeon MY, Heo JY, Park SY, Lee YR, Jang SK, Lee SH, Jang SY, Tak WY, Han KH. Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation. Gut Liver 2017;11:693-701. [PMID: 28651299 DOI: 10.5009/gnl16391] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
17 Zhao Q, Zhu K, Yue J, Qi Z, Jiang S, Xu X, Feng R, Wang R. Comparison of intra-arterial chemoembolization with and without radiotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a meta-analysis. Ther Clin Risk Manag 2017;13:21-31. [PMID: 28053537 DOI: 10.2147/TCRM.S126181] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Cho HJ, Kim SS, Kang SY, Yang MJ, Noh CK, Hwang JC, Lim SG, Shin SJ, Lee KM, Yoo BM, Lee KJ, Kim JH, Cho SW, Cheong JY; Korean Liver Cancer Association. A Proposal for Modification of the Barcelona Clinic Liver Cancer Staging System Considering the Prognostic Implication of Performance Status. Gut Liver 2019;13:557-68. [PMID: 31023007 DOI: 10.5009/gnl18444] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
19 Sherman CB, Behr S, Dodge JL, Roberts JP, Yao FY, Mehta N. Distinguishing Tumor From Bland Portal Vein Thrombus in Liver Transplant Candidates With Hepatocellular Carcinoma: the A-VENA Criteria. Liver Transpl 2019;25:207-16. [PMID: 30246323 DOI: 10.1002/lt.25345] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
20 Brandt AP, Gozzi GJ, Pires Ado R, Martinez GR, Dos Santos Canuto AV, Echevarria A, Di Pietro A, Cadena SM. Impairment of oxidative phosphorylation increases the toxicity of SYD-1 on hepatocarcinoma cells (HepG2). Chem Biol Interact 2016;256:154-60. [PMID: 27417255 DOI: 10.1016/j.cbi.2016.07.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
21 Zhang T, Merle P, Wang H, Zhao H, Kudo M. Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel? Hepatobiliary Surg Nutr 2021;10:180-92. [PMID: 33898559 DOI: 10.21037/hbsn-2021-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Akazawa K, Yoshimura KI, Johnson P, Arai Y; SILIUS study group. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. Lancet Gastroenterol Hepatol. 2018;3:424-432. [PMID: 29631810 DOI: 10.1016/s2468-1253(18)30078-5] [Cited by in Crossref: 75] [Cited by in F6Publishing: 52] [Article Influence: 18.8] [Reference Citation Analysis]
23 Cho YY, Lee M, Kim HC, Chung JW, Kim YH, Gwak GY, Bae SH, Kim do Y, Heo J, Kim YJ. Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis. PLoS One. 2016;11:e0154986. [PMID: 27149067 DOI: 10.1371/journal.pone.0154986] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 4.7] [Reference Citation Analysis]
24 Song SH, Jeong WK, Choi D, Kim YK, Park HC, Yu JI. Evaluation of early treatment response to radiotherapy for HCC using pre- and post-treatment MRI. Acta Radiol 2019;60:826-35. [PMID: 30282483 DOI: 10.1177/0284185118805253] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
25 Liang H, Cui P, Guo Q, Mao X, Wen F, Sun W, Shan M, Lu Z. Prognostic factors of hepatocellular carcinoma patients with portal vein tumor thrombosis treated with transcatheter arterial chemoembolization. Asia Pac J Clin Oncol 2017;13:e331-41. [PMID: 28078806 DOI: 10.1111/ajco.12606] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
26 Kim SS, Nam JS, Cho HJ, Won JH, Kim JW, Ji JH, Yang MJ, Park JH, Noh CK, Shin SJ, Lee KM, Cho SW, Cheong JY. Plasma micoRNA-122 as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2017;32:199-207. [PMID: 27194671 DOI: 10.1111/jgh.13448] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
27 Lee JW, Hwang SH, Kim DY, Han KH, Yun M. Prognostic Value of FDG Uptake of Portal Vein Tumor Thrombosis in Patients With Locally Advanced Hepatocellular Carcinoma. Clin Nucl Med. 2017;42:e35-e40. [PMID: 27775940 DOI: 10.1097/rlu.0000000000001422] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
28 Kong XQ, Dong YP, Wu JX, He JY, Le YY, Du KX, Peng QQ, Li JL. High-biologically effective dose palliative radiotherapy for a tumor thrombus might improve the long-term prognosis of hepatocellular carcinoma: a retrospective study. Radiat Oncol 2017;12:92. [PMID: 28569169 DOI: 10.1186/s13014-017-0831-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
29 Quencer KB, Friedman T, Sheth R, Oklu R. Tumor thrombus: incidence, imaging, prognosis and treatment. Cardiovasc Diagn Ther 2017;7:S165-77. [PMID: 29399520 DOI: 10.21037/cdt.2017.09.16] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 10.0] [Reference Citation Analysis]
30 Gosain R, Anwar S, Miller A, Iyer R, Mukherjee S. Interleukin-6 as a biomarker in patients with hepatobiliary cancers. J Gastrointest Oncol 2019;10:537-45. [PMID: 31183205 DOI: 10.21037/jgo.2019.01.09] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Li MF, Leung HW, Chan AL, Wang SY. Network meta-analysis of treatment regimens for inoperable advanced hepatocellular carcinoma with portal vein invasion. Ther Clin Risk Manag. 2018;14:1157-1168. [PMID: 30013351 DOI: 10.2147/tcrm.s162898] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
32 Cardarelli-Leite L, Chung J, Klass D, Marquez V, Chou F, Ho S, Walton H, Lim H, Tae Wan Kim P, Hadjivassiliou A, Liu DM. Ablative Transarterial Radioembolization Improves Survival in Patients with HCC and Portal Vein Tumor Thrombus. Cardiovasc Intervent Radiol 2020;43:411-22. [PMID: 31909439 DOI: 10.1007/s00270-019-02404-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]